PH12014500904B1 - Antibody formulations and methods - Google Patents

Antibody formulations and methods

Info

Publication number
PH12014500904B1
PH12014500904B1 PH1/2014/500904A PH12014500904A PH12014500904B1 PH 12014500904 B1 PH12014500904 B1 PH 12014500904B1 PH 12014500904 A PH12014500904 A PH 12014500904A PH 12014500904 B1 PH12014500904 B1 PH 12014500904B1
Authority
PH
Philippines
Prior art keywords
methods
antibody formulations
amyloidosis
antibody
formulations
Prior art date
Application number
PH1/2014/500904A
Other languages
English (en)
Other versions
PH12014500904A1 (en
Inventor
Patrick Garidel
Isaac Craig Henderson
Pamela Klein
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of PH12014500904A1 publication Critical patent/PH12014500904A1/en
Publication of PH12014500904B1 publication Critical patent/PH12014500904B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
PH1/2014/500904A 2011-10-25 2012-10-25 Antibody formulations and methods PH12014500904B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551406P 2011-10-25 2011-10-25
PCT/US2012/061950 WO2013063284A1 (en) 2011-10-25 2012-10-25 Antibody formulations and methods

Publications (2)

Publication Number Publication Date
PH12014500904A1 PH12014500904A1 (en) 2014-06-09
PH12014500904B1 true PH12014500904B1 (en) 2019-01-18

Family

ID=48168501

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2014/500904A PH12014500904B1 (en) 2011-10-25 2012-10-25 Antibody formulations and methods

Country Status (19)

Country Link
US (6) US20140302021A1 (https=)
EP (2) EP4088736A1 (https=)
JP (6) JP6431372B2 (https=)
KR (2) KR102196009B1 (https=)
CN (2) CN107233569B (https=)
AU (4) AU2012328739B2 (https=)
BR (1) BR112014009866A2 (https=)
CA (1) CA2853112C (https=)
CL (2) CL2014001081A1 (https=)
CO (1) CO7020867A2 (https=)
EA (1) EA037797B1 (https=)
HK (1) HK1198689A1 (https=)
IL (1) IL232213B (https=)
IN (1) IN2014CN03555A (https=)
MX (2) MX391043B (https=)
PE (2) PE20141413A1 (https=)
PH (1) PH12014500904B1 (https=)
SG (2) SG10201604104PA (https=)
WO (1) WO2013063284A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63930B1 (sr) 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
EP3301115B1 (en) * 2013-05-06 2021-11-10 Sanofi Continuous multistep process for purifying antibodies
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
ES2914781T3 (es) * 2016-06-30 2022-06-16 Prothena Biosciences Ltd Composiciones para el tratamiento de la amiloidosis
US20200233294A1 (en) 2017-03-23 2020-07-23 Sony Corporation Beam irradiation apparatus, and projector with detection function
US11530257B2 (en) 2017-06-29 2022-12-20 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
JP7217287B2 (ja) * 2018-03-23 2023-02-02 プロシーナ バイオサイエンシーズ リミテッド アミロイド症の処置および予防
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP2022520572A (ja) * 2019-02-12 2022-03-31 プロシーナ バイオサイエンシーズ リミテッド 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
EP4582446A3 (en) 2019-03-05 2025-08-13 Prothena Biosciences Limited Methods of treating al amyloidosis
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AU2023361491A1 (en) * 2022-10-12 2025-05-08 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0779694B2 (ja) 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
AU668509B2 (en) 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
US5334380A (en) 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
CA2116684A1 (en) 1991-09-27 1993-04-01 Robert G. Kilbourn Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies
ATE146359T1 (de) 1992-01-21 1997-01-15 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
EP0626850B1 (en) 1992-02-18 2002-05-15 Pharmos Corporation Dry compositions for preparing submicron emulsions
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
AU685784B2 (en) 1993-02-23 1998-01-29 Genentech Inc. Excipient stabilization of polypeptides treated with organic solvents
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
EP0788346B9 (en) 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulsified drug delivery systems
DE69530196T2 (de) 1994-06-02 2003-11-20 Elan Drug Delivery Ltd Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
ATE252373T1 (de) 1994-08-04 2003-11-15 Elan Drug Delivery Ltd Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung
US5593824A (en) 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
DE69628007T2 (de) 1995-06-07 2003-11-27 Elan Drug Delivery Ltd., Ruddington Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
USRE38431E1 (en) 1995-12-01 2004-02-17 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
GB9705588D0 (en) 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
WO1998043610A1 (en) 1997-04-03 1998-10-08 Elias Hakalehto A method for producing jelly sweets which contain antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
CA2302275C (en) 1997-09-19 2009-12-08 Shire Laboratories, Inc. Solid solution beadlet
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
ID24279A (id) 1998-06-26 2000-07-13 Otsuka Pharma Co Ltd Komposisi kering yang terlarut dalam air
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
CA2346539C (en) 1998-10-05 2006-09-12 The Penn State Research Foundation Compositions and methods for enhancing receptor-mediated cellular internalization
PL200941B1 (pl) 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
CA2361424C (en) 1999-02-08 2009-04-28 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
JP2002542183A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 成形可能な乾燥した医薬製剤
ATE274955T1 (de) 1999-05-03 2004-09-15 Battelle Memorial Institute Arzneizusammensetzungen zur aerosolbildung und zu inhalationszwecken
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
GB9914412D0 (en) 1999-06-22 1999-08-18 Worrall Eric E Method for the preservation of viruses,bacteria and biomolecules
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
JP3884652B2 (ja) 1999-12-14 2007-02-21 サーモ エレクトロン コーポレイション−ポイント オブ ケア エンド ラピッド ダイアグノスティックス ポリペプチドおよび抗原の安定化希釈液
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US7141236B2 (en) 2000-07-28 2006-11-28 Nektar Therapeutics Methods and compositions for delivering macromolecules to or via the respiratory tract
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP4460892B2 (ja) 2001-06-21 2010-05-12 ジェネンテック インコーポレイテッド 徐放性組成物
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
US6646394B2 (en) * 2001-07-09 2003-11-11 Nissan Motor Co., Ltd. Control device for plurality of rotating electrical machines
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US6982080B2 (en) 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
WO2003087335A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US20040120956A1 (en) * 2002-06-27 2004-06-24 Song Xiao-Yu R. CNGH0004 polypeptides, antibodies, compositions, methods and uses
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CA2503946C (en) 2002-11-01 2016-08-16 Glaxosmithkline Biologicals S.A. Drying process
CA2504610C (en) 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
CN1745170A (zh) 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 生物活性材料的高压喷雾干燥
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
SI21639A (sl) 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
DK1755659T3 (da) 2004-03-24 2012-02-27 Abbott Biotherapeutics Corp Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
GB0409795D0 (en) 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7811563B2 (en) * 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
AU2005304035B2 (en) 2004-11-09 2010-07-22 Santen Sas Ophthalmic oil-in-water type emulsion with stable positive zeta potential
US20060124266A1 (en) * 2004-11-23 2006-06-15 Novozymes North America, Inc. Use of cyclodextrins for reducing deposits during paper production
US7910086B1 (en) 2005-01-04 2011-03-22 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7919072B1 (en) 2005-01-04 2011-04-05 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7541046B1 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7879313B1 (en) 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8048453B1 (en) 2005-01-04 2011-11-01 Gp Medical, Inc. Pharmaceutical composition of nanoparticles for protein drug delivery
US7897585B1 (en) 2005-01-04 2011-03-01 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7993625B1 (en) 2005-01-04 2011-08-09 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
MY139088A (en) 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
EP1871803B1 (en) 2005-04-18 2013-02-20 Yeda Research And Development Company Limited Stabilized anti-hepatitis b (hbv) antibody formulations
BRPI0608376A8 (pt) 2005-04-22 2018-10-16 Lilly Co Eli composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
KR101457223B1 (ko) 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
CN103145842A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
US7956160B2 (en) 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
MY155286A (en) * 2005-12-12 2015-09-30 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylated in the variable region
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
DE102006030164A1 (de) 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
GB0621707D0 (en) 2006-10-31 2006-12-13 Univ London Pharmacy Formulations for delivery via pressurised metered dose inhalers
JP5410985B2 (ja) 2006-12-05 2014-02-05 クルセル ホランド ベー ヴェー 液体抗狂犬病抗体製剤
CL2007003583A1 (es) * 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
US7883664B2 (en) 2007-06-27 2011-02-08 University Of North Carolina At Charlotte Microwave drying process for vitrification of biologics
US8268354B2 (en) 2007-11-07 2012-09-18 Aridis Pharmaceuticals Sonic low pressure spray drying
BRPI0820819B1 (pt) 2007-12-21 2021-06-08 F. Hoffmann-La Roche Ag formulação de anticorpos humanizados b-ly 1 e seu uso
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
DK2237803T3 (en) * 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
EP2303226B1 (en) 2008-06-25 2016-03-23 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
ES2531385T3 (es) 2008-09-19 2015-03-13 Hoffmann La Roche Formulación que comprende un anticuerpo contra la selectina P
CN102281901A (zh) * 2008-11-20 2011-12-14 弗·哈夫曼-拉罗切有限公司 治疗性蛋白质制剂
CN201401081Y (zh) 2009-03-26 2010-02-10 徐谦 一种两折型合页
CN201553504U (zh) * 2009-10-30 2010-08-18 浙江浦江缆索有限公司 一种悬索拉索成圈用120t成圈机
KR102345173B1 (ko) * 2014-03-14 2021-12-29 이나뜨 파르마 에스.에이. 증가된 안정성을 가진 인간화 항체

Also Published As

Publication number Publication date
US20180235887A1 (en) 2018-08-23
SG11201401360XA (en) 2014-05-29
US20150344555A1 (en) 2015-12-03
HK1243344A1 (zh) 2018-07-13
JP2017057218A (ja) 2017-03-23
EP4088736A1 (en) 2022-11-16
WO2013063284A1 (en) 2013-05-02
EP2771029A4 (en) 2015-07-01
HK1198689A1 (en) 2015-05-29
US9089529B2 (en) 2015-07-28
US20140302021A1 (en) 2014-10-09
CN107233569A (zh) 2017-10-10
KR20140123475A (ko) 2014-10-22
PH12014500904A1 (en) 2014-06-09
KR20210003928A (ko) 2021-01-12
CA2853112C (en) 2018-08-21
US20130295082A1 (en) 2013-11-07
EP2771029A1 (en) 2014-09-03
EA201490850A1 (ru) 2015-03-31
SG10201604104PA (en) 2016-07-28
CO7020867A2 (es) 2014-08-11
MX2014004786A (es) 2014-08-21
JP2014530917A (ja) 2014-11-20
US9884020B2 (en) 2018-02-06
MX391043B (es) 2025-03-21
US10517830B2 (en) 2019-12-31
MX354988B (es) 2018-03-28
NZ623606A (en) 2015-12-24
PE20191242A1 (es) 2019-09-16
CA2853112A1 (en) 2013-05-02
JP2023116817A (ja) 2023-08-22
JP2022033254A (ja) 2022-02-28
CL2014001081A1 (es) 2014-11-21
IL232213B (en) 2019-03-31
US20160310430A1 (en) 2016-10-27
PE20141413A1 (es) 2014-10-25
JP2020063307A (ja) 2020-04-23
CN104023743B (zh) 2017-05-03
KR102276161B1 (ko) 2021-07-14
IL232213A0 (en) 2014-06-30
CL2017002283A1 (es) 2018-05-18
IN2014CN03555A (https=) 2015-07-03
KR102196009B1 (ko) 2021-01-04
AU2022202649B2 (en) 2025-07-03
JP6431372B2 (ja) 2018-11-28
EA037797B1 (ru) 2021-05-21
BR112014009866A2 (pt) 2018-09-04
AU2017258950A1 (en) 2017-11-30
AU2012328739B2 (en) 2017-11-30
AU2022202649A1 (en) 2022-05-12
CN107233569B (zh) 2021-08-31
US20210077407A1 (en) 2021-03-18
JP2018184478A (ja) 2018-11-22
AU2020201147A1 (en) 2020-03-05
AU2012328739A1 (en) 2014-04-24
CN104023743A (zh) 2014-09-03

Similar Documents

Publication Publication Date Title
PH12014500904B1 (en) Antibody formulations and methods
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
EP4450130A3 (en) Formulations of enzalutamide
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MX347020B (es) Anticuerpo contra el csf-1r.
MX2016004927A (es) Composiciones utiles para tratar trastornos relacionados con kit.
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
MX359769B (es) Metodos para descelularizar huesos.
IN2014CN04014A (https=)
MX360774B (es) Antagonistas de progesterona.
IN2014DN09450A (https=)
IN2014DN00254A (https=)
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
MX347541B (es) Analogos de acido sialico.
GB201107985D0 (en) Process
WO2013009678A3 (en) Compositions and methods for the treatment of norovirus infection
WO2013013238A3 (en) Compounds and related compositions and methods of use
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
UA66165U (ru) Применение витаминной композиции, которая содержит витамины С и К3, в качестве средства для лечения вирусных инфекций
UA72478U (ru) Применение полентара как средства фригопротекторного действия